Bavarian Nordic scraps RSV vaccine after PhIII trial misses the bar on preventing severe symptoms

Bavar­i­an Nordic is scrap­ping its RSV pro­gram af­ter its vac­cine can­di­date flunked a large Phase III tri­al that had en­rolled more than 20,000 el­der­ly pa­tients.

Its vac­cine, MVA-BN RSV, flunked a co-pri­ma­ry end­point in the study — the can­di­date on­ly showed a 42.9% ef­fi­ca­cy in pre­vent­ing more se­vere symp­toms of low­er res­pi­ra­to­ry tract dis­ease. MVA-BN RSV did hit the oth­er pri­ma­ry end­point, demon­strat­ing a 59% ef­fi­ca­cy in pre­vent­ing at least two symp­toms of the dis­ease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN